Carvedilol

Hepatology[Jour] AND 82[volume] AND 1[issue] 肝脏病学82卷1期 https://journals-lww-com.libproxy1.nus.edu.sg/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 The dynamic duo: How tumor-associated macrophages and tumor cells team up in cholangiocarcinoma “黄金搭档”：胆管癌中肿瘤相关巨噬细胞与肿瘤细胞如何协同作用 Li, Binbin; Ilyas, Sumera I. Hepatology. 82(1):1-2, July 2025. 2 Two heads are better than one: The synergy of carvedilol and simvastatin 双剑合璧：卡维地洛与辛伐他汀的协同作用 Kumar, Prabhat; Arab, Juan Pablo Hepatology. 82(1):3-4, July 2025. 3 Not so subclinical: Is early thyroid disease an untapped avenue to protect children from MASLD? 并非那么“亚临床”：早期甲状腺疾病是否是保护儿童免受代谢障碍相关脂肪性肝病（MASLD）侵害的未开发途径？ Marek, George Hepatology. 82(1):5-6, July 2025. 4 Genes that fit just right: Unzipping the genome of fatty liver disease 基因恰到好处：解开脂肪肝疾病的基因组密码 Sample, Jack W. Hepatology. 82(1):7-8, July 2025. Editorials（社论） 5 New ubiquitomic subtypes in HCC: Insights for future therapeutic approaches 肝细胞癌（HCC）中新的泛素组学亚型：为未来治疗策略提供见解 Nakagawa, Hayato Hepatology. 82(1):9-11, July 2025. 6 Mitochondrial genome diversity drives heterogeneity in HCC 线粒体基因组多样性驱动肝细胞癌的异质性 Shibata, Tatsuhiro; Hoshida, Yujin Hepatology. 82(1):12-13, July 2025. 7 Cell-to-cell signaling cross-talk in liver regeneration: A prostaglandin-Wnt axis 肝脏再生中的细胞间信号串扰：前列腺素-Wnt轴 Apte, Udayan Hepatology. 82(1):14-15, July 2025. 8 Utilizing viral RNA fragments to limit acute inflammation 利用病毒RNA片段限制急性炎症 Zhao, Chunyuan; Zhao, Wei Hepatology. 82(1):16-18, July 2025. 9 Functional humoral immunity is crucial to outcomes in severe alcohol-associated hepatitis 功能性体液免疫对严重酒精相关性肝炎的预后至关重要 McGettigan, Brett M.; A. Osna, Natalia Hepatology. 82(1):19-21, July 2025. 10 Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions 通过超变区1插入对丙型肝炎病毒免疫逃逸的精细调控 Colpitts, Che C.; Baumert, Thomas F. Hepatology. 82(1):22-24, July 2025. Original Articles（论著） Liver Cancer（肝癌） 11 The co-location of MARCO+ tumor-associated macrophages and CTSE+ tumor cells determined the poor prognosis in intrahepatic cholangiocarcinoma MARCO+肿瘤相关巨噬细胞与CTSE+肿瘤细胞的共定位决定肝内胆管癌的不良预后 Fan, Guangyu; Tao, Changcheng; Li, Lin; More Hepatology. 82(1):25-41, July 2025. 12 Integrated ubiquitomics characterization of hepatocellular carcinomas 肝细胞癌的整合泛素组学特征分析 Lin, Xiao-Tong; Luo, Yuan-Deng; Mao, Cui; More Hepatology. 82(1):42-58, July 2025. 13 Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution 单细胞分辨率下揭示肝细胞癌中不稳定线粒体DNA突变的双向进化 Zhou, Kaixiang; Wang, Zhenni; Guo, Wenjie; More Hepatology. 82(1):59-76, July 2025. Liver Pathobiology（肝脏病理生物学） 14 PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice PGD2/DP1轴通过在小鼠库普弗细胞（KCs）中分泌Wnt2促进肝脏再生 Li, Juanjuan; Zheng, Yinghong; Duan, Zhenzhen; More Hepatology. 82(1):77-91, July 2025. 15 The desulfinylation enzyme sulfiredoxin-1 attenuates HSC activation and liver fibrosis by modulating the PTPN12-NLRP3 axis 脱亚磺酰化酶硫氧还蛋白还原酶-1通过调节PTPN12-NLRP3轴减弱肝星状细胞（HSC）活化和肝纤维化 Kim, Jong-Won; Tung, Hung-Chun; Ke, Mengyun; More Hepatology. 82(1):92-109, July 2025. 16 Harnessing ZIKV NS2A RNA for alleviating acute hepatitis and cytokine release storm by targeting translation machinery 利用寨卡病毒NS2A RNA通过靶向转化机制缓解急性肝炎和细胞因子释放风暴 Zhu, Jingfei; Wu, Rongsheng; Yang, Tao; More Hepatology. 82(1):110-126, July 2025. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门静脉高压） 17 Viral antibody response predicts morbidity and mortality in alcohol-associated hepatitis 病毒抗体反应可预测酒精相关性肝炎的发病率和死亡率 Hsu, Cynthia L.; Wang, Limin; Maestri, Evan; More Hepatology. 82(1):127-139, July 2025. 18 Hemodynamic effects of carvedilol plus simvastatin in cirrhosis with severe portal hypertension and suboptimal response to β-blockers: A double-blind, placebo-controlled, randomized trial 卡维地洛联合辛伐他汀对β受体阻滞剂反应不佳的严重门静脉高压肝硬化患者的血流动力学影响：一项双盲、安慰剂对照、随机试验 Alvarado-Tapias, Edilmar; Brujats, Anna; Puente, Angela; More Hepatology. 82(1):140-154, July 2025. Pediatrics（儿科） 19 Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study 代谢功能障碍相关脂肪性肝病青少年中亚临床甲状腺功能减退症的患病率及纵向促甲状腺激素变化：一项观察性研究 Untalan, Matthew; A. Crimmins, Nancy; Yates, Katherine P.; More Hepatology. 82(1):155-164, July 2025. Steatohepatitis（脂肪性肝炎） 20 A functional genomic framework to elucidate novel causal metabolic dysfunction–associated fatty liver disease genes 功能基因组学框架用于阐明新型代谢功能障碍相关脂肪性肝病致病基因 Saliba-Gustafsson, Peter; Justesen, Johanne M.; Ranta, Amanda; More Hepatology. 82(1):165-183, July 2025. 21 Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction–associated steatotic liver disease progression by exerting dual regulation on HIF-1α 肠道白细胞介素-33（IL-33）通过对缺氧诱导因子-1α（HIF-1α）的双重调控，促进微生物群来源的氧化三甲胺（TMAO）合成，并驱动代谢功能障碍相关脂肪性肝病（MASLD）的进展 Hai, Suping; Li, Xitang; Xie, Erliang; More Hepatology. 82(1):184-198, July 2025. Viral Hepatitis（病毒性肝炎） 22 Prevalence of HCV HVR1 insertions and their role in antibody evasion 丙型肝炎病毒（HCV）超变区1（HVR1）插入的流行情况及其在抗体逃逸中的作用 Olesen, Christina Holmboe; Collignon, Laura; Velázquez-Moctezuma, Rodrigo; More Hepatology. 82(1):199-211, July 2025. Reviews（综述） 23 Benefit and harm of waiting time in liver transplantation for HCC 肝细胞癌（HCC）肝移植等待时间的利弊 van der Meeren, Pam Elisabeth; de Wilde, Roeland Frederik; Sprengers, Dave; More Hepatology. 82(1):212-231, July 2025. 24 Emerging and potential use of CRISPR in human liver disease CRISPR在人类肝脏疾病中的新兴应用及潜在用途 Adlat, Salah; Vázquez Salgado, Alexandra M.; Lee, Markcus; More Hepatology. 82(1):232-253, July 2025. 25 New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease 酒精相关性肝病中酒精戒断和复饮的分子基础新见解 Diaz, Luis Antonio; Winder, Gerald Scott; Leggio, Lorenzo; More Hepatology. 82(1):254-271, July 2025. Practice Guidance（实践指南） 26 Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma 重要更新：美国肝病研究学会（AASLD）关于肝细胞癌预防、诊断和治疗的实践指南 Taddei, Tamar H.; Brown, Daniel B.; Yarchoan, Mark; More Hepatology. 82(1):272-274, July 2025. Correspondence（读者来信） 27 Letter to the Editor: Prevalence of subclinical hypothyroidism and longitudinal thyroid stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study 致编辑的信：代谢功能障碍相关脂肪性肝病青少年中亚临床甲状腺功能减退症的患病率及纵向促甲状腺激素变化：一项观察性研究 Di Sessa, Anna; Miraglia del Giudice, Emanuele Hepatology. 82(1):E1-E2, July 2025. 28 Reply: Prevalence of subclinical hypothyroidism and longitudinal thyroid stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study 回复：代谢功能障碍相关脂肪性肝病青少年中亚临床甲状腺功能减退症的患病率及纵向促甲状腺激素变化：一项观察性研究 Thaker, Vidhu V.; Crimmins, Nancy; Yates, Katherine P.; More Hepatology. 82(1):E3-E4, July 2025. 29 Letter to the Editor: Mean arterial pressure as a complex treatment target in patients with cirrhosis and acute kidney injury 致编辑的信：肝硬化合并急性肾损伤患者的平均动脉压作为复杂治疗目标 Cardoso, Filipe S. Hepatology. 82(1):E5-E6, July 2025. 30 Letter to the Editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcia 致编辑的信：关于在肝硬化合并肌少症患者中使用LPCN 1148的考量 Tantai, Xinxing; Li, Lu; Dai, Shejiao Hepatology. 82(1):E7-E8, July 2025. 31 Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcia 回复：关于在肝硬化合并肌少症患者中使用LPCN 1148的考量 Bruno, Benjamin J.; Weavil, Joshua C.; Ogle, Jonathan; More Hepatology. 82(1):E9-E10, July 2025. 32 Letter to the Editor: Different phenotypes of CMRFs lead to different pathophysiological processes among individuals with MASLD/MetALD 致编辑的信：代谢功能障碍相关脂肪性肝病（MASLD）/代谢相关酒精性肝病（MetALD）患者中细胞因子调节因子（CMRFs）的不同表型导致不同的病理生理过程 Li, Zheng; Tang, Xiaolong; Li, Zhiping; More Hepatology. 82(1):E11-E12, July 2025. 33 Reply: Different phenotypes of CMRFs lead to different pathophysiological processes among individuals with MASLD/MetALD 回复：代谢功能障碍相关脂肪性肝病（MASLD）/代谢相关酒精性肝病（MetALD）患者中细胞因子调节因子（CMRFs）的不同表型导致不同的病理生理过程 Kim, Hyun-seok; Kwak, Minsun; Yang, Ju Dong Hepatology. 82(1):E13-E14, July 2025. 34 Letter to the Editor: Targeted enteral feeding for malnutrition in liver transplant candidates 致编辑的信：针对肝移植候选人的营养不良进行靶向肠内喂养 Chen, Qingyu Hepatology. 82(1):E15, July 2025. 35 Reply: Targeted enteral feeding for malnutrition in liver transplant candidates 回复：针对肝移植候选人的营养不良进行靶向肠内喂养 Chapman, Brooke; Wong, Darren; Sinclair, Marie; More Hepatology. 82(1):E16-E17, July 2025. 36 Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance? 致编辑的信：原发性硬化性胆管炎与自身免疫性肝炎——是截然不同还是存在共同的自身免疫倾向？ Grønbæk, Lisbet; Vilstrup, Hendrik; Jepsen, Peter Hepatology. 82(1):E18-E19, July 2025. 37 Reply: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance? 回复：原发性硬化性胆管炎与自身免疫性肝炎——是截然不同还是存在共同的自身免疫倾向？ Lundberg Båve, Aiva; von Seth, Erik; Ingre, Michael; More Hepatology. 82(1):E20, July 2025. Retractions（撤稿声明） 38 Retraction: α-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca2+- and PKC-dependent stimulation of cAMP 撤稿声明：α-1肾上腺素能受体激动剂通过钙离子（Ca2+）和蛋白激酶C（PKC）依赖的环磷酸腺苷（cAMP）刺激调节胆总管结扎（BDL）大鼠的胆管分泌 LeSage, Gene D.; Alvaro, Domenico; Glaser, Shannon; More Hepatology. 82(1):E21, July 2025. 39 Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8 撤稿声明：γ-氨基丁酸（GABA）通过激活钙离子/钙调蛋白激酶I（Ca2+/CaMK I）依赖的腺苷酸环化酶8诱导小胆管细胞向大胆管细胞分化 Mancinelli, Romina; Franchitto, Antonio; Glaser, Shannon; More Hepatology. 82(1):E22, July 2025. Hepatology[Jour] AND 82[volume] AND 2[issue] 肝脏病学82卷2期 https://journals-lww-com.libproxy1.nus.edu.sg/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 Deep learning’s crystal ball: Predicting HCC surgery success with multimodal imaging 深度学习的“水晶球”：利用多模态成像预测肝细胞癌（HCC）手术成功 Chodha, Ankit Hepatology. 82(2):275-276, August 2025. 2 Better late than resectable: Combination therapy finds its moment 对于晚期，优于可切除的情况：联合疗法迎来高光时刻 Khan, Sarah Hepatology. 82(2):277-278, August 2025. 3 Decoding liver risk: A deep dive into the Baveno VII “Rule-of-Five”criteria 解读肝脏风险：深入剖析Baveno VII“五规则”标准 Rama, Kaanthi; Arab, Juan Pablo Hepatology. 82(2):279-280, August 2025. 4 2D-SWE in MASLD: Should we utilize it more with these new cutoffs? 代谢障碍相关脂肪性肝病（MASLD）中的二维剪切波弹性成像（2D-SWE）：是否应采用这些新临界值以扩大其应用？ Udompap, Prowpanga Hepatology. 82(2):281-282, August 2025. Editorials（社论） 5 Cracking HCC: Targeting diacylglycerol kinase eta to tackle therapy resistance and cancer stemness 破解肝细胞癌：靶向二酰甘油激酶η以应对治疗耐药性和癌症干细胞特性 Song, Guisheng Hepatology. 82(2):283-285, August 2025. 6 Mechanocrine signaling, Yap, HB-EGF, and liver regeneration 机械分泌信号传导、Yap、肝素结合表皮生长因子（HB-EGF）与肝脏再生 Michalopoulos, George K. Hepatology. 82(2):286-288, August 2025. 7 From micronutrient to mechanism: Magnesium and the CNNM4 puzzle in alcohol-associated liver disease 从微量元素到作用机制：酒精相关肝病中镁与CNNM4的谜团 Rungratanawanich, Wiramon; Liangpunsakul, Suthat; Ma, Jing Hepatology. 82(2):289-292, August 2025. Original Articles（论著） Immune-Mediated Diseases, DILI, and Biliary Tract Disease（免疫介导疾病、药物性肝损伤和胆道疾病） 8 Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity Stard1通过增强对胆汁酸肝毒性的敏感性促进胆汁淤积性肝损伤和疾病进展 Conde de la Rosa, Laura; Fàbrega, Laura; Torres, Sandra; More Hepatology. 82(2):293-307, August 2025. Liver Cancer（肝癌） 9 DGKH-mediated phosphatidic acid oncometabolism as a driver of self-renewal and therapy resistance in HCC 二酰甘油激酶η（DGKH）介导的磷脂酸肿瘤代谢是肝细胞癌自我更新和治疗耐药的驱动因素 Loh, Jia Jian; Ng, Kai Yu; Huang, Ianto Bosheng; More Hepatology. 82(2):308-325, August 2025. 10 Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice 用针对磷脂酰肌醇蛋白聚糖3（glypican 3）的人白细胞抗原A2（HLA-A2）限制性小鼠T细胞受体工程化改造的人T细胞可有效控制小鼠体内的人肝细胞癌 Vercher, Enric; Covo-Vergara, Ángela; Conde, Enrique; More Hepatology. 82(2):326-343, August 2025. 11 Multimodal multiphasic preoperative image-based deep-learning predicts HCC outcomes after curative surgery 基于多模态多期术前影像的深度学习预测肝细胞癌根治术后的预后 Hui, Rex Wan-Hin; Chiu, Keith Wan-Hang; Lee, I-Cheng; More Hepatology. 82(2):344-356, August 2025. 12 Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages 多中心回顾性GUIDANCE001研究：比较经动脉化疗栓塞术联合或不联合酪氨酸激酶抑制剂和免疫检查点抑制剂作为转化疗法治疗不可切除肝细胞癌——在中期或晚期而非早期患者中显示生存获益 Yang, Da-Long; Ye, Lin; Zeng, Fan-Jian; More Hepatology. 82(2):357-369, August 2025. Liver Pathobiology（肝脏病理生物学） 13 Stretch-induced hepatic endothelial mechanocrine promotes hepatocyte proliferation 牵张诱导的肝内皮细胞机械分泌促进肝细胞增殖 Wu, Yi; Li, Linda; Li, Wang; More Hepatology. 82(2):370-387, August 2025. 14 Modulatory effects of CNNM4 on protein-l-isoaspartyl-O-methyltransferase repair function during alcohol-induced hepatic damage 酒精性肝损伤期间CNNM4对蛋白质-L-异天冬氨酰-O-甲基转移酶修复功能的调节作用 González-Recio, Irene; Goikoetxea-Usandizaga, Naroa; Rejano-Gordillo, Claudia M.; More Hepatology. 82(2):388-404, August 2025. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门静脉高压） 15 Comparing the cost of cirrhosis to other common chronic diseases: A longitudinal study in a large national insurance database 肝硬化与其他常见慢性疾病成本的比较：一项基于大型国家保险数据库的纵向研究 Obradović, Filip; Vitello, Dominic J.; Hasjim, Bima J.; More Hepatology. 82(2):405-421, August 2025. 16 Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death 基于肝脏硬度和血小板计数对代偿期进展性慢性肝病（cACLD）和临床显著性门静脉高压（CSPH）的Baveno VII标准的验证与扩展：与肝失代偿和死亡风险的相关性 Vutien, Philip; Barnard Giustini, Abbey; Kim, Nicole J.; More Hepatology. 82(2):422-437, August 2025. Steatohepatitis（脂肪性肝炎） 17 HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathway HAF通过转录调控核因子-κB（NF-κB）通路防止肝细胞凋亡和向代谢相关脂肪性肝炎（MASH）及肝细胞癌进展 Acuña-Pilarte, Karen; Reichert, Ethan C.; Green, Yangsook Song; More Hepatology. 82(2):438-453, August 2025. 18 Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: A multilevel random effects model meta-analysis 二维剪切波弹性成像超声在代谢相关脂肪性肝病（MASLD）肝纤维化评估中的诊断准确性：一项多水平随机效应模型荟萃分析 Indre, Madalina-Gabriela; Leucuta, Dan-Corneliu; Lupsor-Platon, Monica; More Hepatology. 82(2):454-469, August 2025. Viral Hepatitis（病毒性肝炎） 19 Enhanced hepatitis B virus–specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection 在慢性乙型肝炎病毒感染小鼠模型中，联合中和抗体疗法和DNA疫苗接种增强乙型肝炎病毒特异性免疫 Beretta, Maxime; Vesin, Benjamin; Wei, Yu; More Hepatology. 82(2):470-486, August 2025. Reviews（综述） 20 Metabolic dysfunction-associated steatotic liver disease and the heart 代谢功能障碍相关脂肪性肝病与心脏 Driessen, Stan; Francque, Sven M.; Anker, Stefan D.; More Hepatology. 82(2):487-503, August 2025. 21 Navigating the “specific etiology” steatohepatitis category: Evaluation and management of nonalcohol/nonmetabolic dysfunction–associated steatohepatitis “特定病因”脂肪性肝炎类别的探索：非酒精/非代谢功能障碍相关脂肪性肝炎的评估与治疗 Khan, Mohammad Qasim; Hassan, Sara; Lizaola-Mayo, Blanca C.; More Hepatology. 82(2):504-521, August 2025. 22 Immunogenomics of cholangiocarcinoma 胆管癌的免疫基因组学 Gehl, Virag; O’Rourke, Colm J.; Andersen, Jesper B. Hepatology. 82(2):522-539, August 2025. Correspondence（通信） 23 Letter to the Editor: Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC 致编辑的信：脂质代谢重编码的综合分析拓展了肝细胞癌的精准医疗 Du, Rui; Yang, Yanfei; Su, Yuzhe; More Hepatology. 82(2):E23-E24, August 2025. 24 Reply: Comprehensive profiling of lipid metabolic reprogramming expands precision medicine for HCC 回复：脂质代谢重编码的综合分析拓展了肝细胞癌的精准医疗 Liu, Qingbin; Qi, Jingjing; Yu, Yong; More Hepatology. 82(2):E25-E26, August 2025. 25 Letter to the Editor: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies 致编辑的信：膳食纤维和全谷物摄入量与肝癌风险的关系——两项前瞻性队列研究及前瞻性研究的系统回顾和荟萃分析 Huang, Wang; Sun, Hao Hepatology. 82(2):E27, August 2025. 26 Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies 回复：膳食纤维和全谷物摄入量与肝癌风险的关系——两项前瞻性队列研究及前瞻性研究的系统回顾和荟萃分析 Watling, Cody Z.; Wojt, Aika; Florio, Andrea A.; More Hepatology. 82(2):E28-E29, August 2025. 27 Letter to the Editor: Dynamic frailty trajectories and temporal measurement challenges in assessing liver transplantation survival benefit 致编辑的信：评估肝移植生存获益时的动态衰弱轨迹和时间测量挑战 Zhang, Yazhen Hepatology. 82(2):E30, August 2025. 28 Letter to the Editor: How to count from 0 to 4 without skipping a number 致编辑的信：如何从0数到4而不跳过数字 Kim, W. Ray; Sripongpun, Pimsiri; Mannalithara, Ajitha; More Hepatology. 82(2):E31-E32, August 2025. 29 Reply: How to count from 0 to 4 without skipping a number 回复：如何从0数到4而不跳过数字 Sterling, Richard K.; Patel, Keyur; Duarte-Rojo, Andres; More Hepatology. 82(2):E33-E34, August 2025. Errata（勘误） 30 Erratum: Insufficient radiofrequency ablation promotes hepatocellular carcinoma metastasis through N6-methyladenosine mRNA methylation-dependent mechanism 勘误：射频消融不足通过N6-甲基腺苷mRNA甲基化依赖机制促进肝细胞癌转移 Su, Tianhong; Huang, Manling; Liao, Junbin; More Hepatology. 82(2):E35-E36, August 2025. 31 Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans 勘误：三乙烯四胺和青霉胺对肠道铜吸收的影响：一项在健康人群中进行的64Cu PET/CT机制研究 Kirk, Frederik Teicher; Munk, Ditte Emilie; Swenson, Eugene Scott; More Hepatology. 82(2):E37, August 2025. 32 Erratum: Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells 勘误：激活p62-Keap1-NRF2通路可保护肝细胞癌细胞免受铁死亡 Xiaofang, Sun; Zhanhui, Ou; Ruochan, Chen; More Hepatology. 82(2):E38-E39, August 2025. 33 Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages 勘误：多中心回顾性GUIDANCE001研究比较经动脉化疗栓塞术联合或不联合酪氨酸激酶抑制剂和免疫检查点抑制剂作为转化疗法治疗不可切除肝细胞癌——在中期或晚期而非早期患者中显示生存获益 Yang, Da-Long; Ye, Lin; Zeng, Fan-Jian; More Hepatology. 82(2):E40, August 2025. Hepatology[Jour] AND 82[volume] AND 3[issue] 肝脏病学 82卷 3期 https://journals-lww-com.libproxy1.nus.edu.sg/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 Honey, I shrunk the tumor: Downstaging HCC before liver transplantation 亲，我缩小了肿瘤：肝移植前肝细胞癌（HCC）的降期治疗 Grady, John; Arab, Juan Pablo Hepatology. 82(3):541-542, September 2025. 2 Surging sludge: Intrahepatic cholangiocarcinoma mortality on the rise worldwide 泥沙涌动：全球肝内胆管癌死亡率上升 Wilechansky, Robert M. Hepatology. 82(3):543-544, September 2025. 3 Hepatic stellate cells and macrophages: Key players in HCC immune suppression 肝星状细胞和巨噬细胞：肝细胞癌免疫抑制的关键参与者 Erickson, Hanna Hepatology. 82(3):545-546, September 2025. 4 Unlocking immunity’s memory: Epigenetic keys to HBV control 解锁免疫记忆：乙型肝炎病毒（HBV）控制的表观遗传关键 McGettigan, Brett M. Hepatology. 82(3):547-548, September 2025. Editorial（社论） 5 Unveiling the immune landscape of IDH1-mutant cholangiocarcinoma: Pathways to new therapies 揭示IDH1突变型胆管癌的免疫格局：通向新疗法的途径 Li, Binbin; Ilyas, Sumera I. Hepatology. 82(3):549-551, September 2025. Original Articles（论著） Immune-Mediated Diseases, DILI, and Biliary Tract Disease（免疫介导疾病、药物性肝损伤和胆道疾病） 6 Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation 白细胞介素8-CXCR2介导的胆道闭锁相关中性粒细胞胞外诱捕网形成及中性粒细胞胞外诱捕网诱导的星状细胞激活 Luo, Yuhuan; Fraser, Lisa; Jezykowski, Julia; More Hepatology. 82(3):552-565, September 2025. Liver Cancer（肝癌） 7 Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution 单细胞分辨率下肝细胞癌静脉肿瘤血栓的独特免疫微环境 Zhou, Kai-Qian; Zhong, Yu-Chen; Song, Min-Fang; More Hepatology. 82(3):566-581, September 2025. 8 Genomic and the tumor microenvironment heterogeneity in multifocal hepatocellular carcinoma 多灶性肝细胞癌的基因组和肿瘤微环境异质性 Yang, Yongheng; Ni, Qingqiang; Li, Hongguang; More Hepatology. 82(3):582-598, September 2025. 9 Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma 肿瘤来源的CCL2驱动IDH1突变型胆管癌肿瘤生长和免疫抑制 Zabransky, Daniel J.; Kartalia, Emma; Lee, Jae W.; More Hepatology. 82(3):599-611, September 2025. 10 Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study 肝移植前肝细胞癌降期治疗：一项全国多中心前瞻性队列研究的结果 Xu, Edison; Tabrizian, Parissa; Gutierrez, Julio; More Hepatology. 82(3):612-625, September 2025. 11 International trends in biliary tract cancer–related mortality, 2000–2022: An observational study of the World Health Organization Mortality Database 2000 - 2022年胆道癌相关死亡率的国际趋势：世界卫生组织死亡数据库的观察性研究 Vu, Quynh Thi; Nishimura, Yoshito; Harada, Ko; More Hepatology. 82(3):626-637, September 2025. Liver Pathobiology（肝脏病理生物学） 12 Human-induced pluripotent stem cell–based hepatic modeling of lipid metabolism–associated TM6SF2-E167K variant 基于人类诱导多能干细胞模拟脂质代谢相关TM6SF2-E167K变异的肝脏模型 Faccioli, Lanuza A.P.; Sun, Yiyue; Animasahun, Olamide; More Hepatology. 82(3):638-654, September 2025. 13 CX3CR1+ macrophages interact with HSCs to promote HCC through CD8+ T-cell suppression CX3CR1+巨噬细胞与肝星状细胞相互作用通过抑制CD8+ T细胞促进肝细胞癌 Jeong, Jong-Min; Choi, Sung Eun; Shim, Young-Ri; More Hepatology. 82(3):655-668, September 2025. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门静脉高压） 14 Plasma FSTL-1 as a noninvasive diagnostic biomarker for patients with advanced liver fibrosis 血浆FSTL-1作为晚期肝纤维化患者的无创诊断生物标志物 Li, Wenzhu; Chi, Yongquan; Xiao, Xuan; More Hepatology. 82(3):669-682, September 2025. 15 Lhx2 specifically expressed in HSCs promotes liver regeneration and inhibits liver fibrosis 肝星状细胞特异性表达的Lhx2促进肝再生并抑制肝纤维化 Tao, Jiawang; Wu, Zichao; Liang, Yanran; More Hepatology. 82(3):683-701, September 2025. Steatohepatitis（脂肪性肝炎） 16 HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation HNF4α-CDKL3轴通过非经典磷酸化靶向FoxO1限制代谢相关脂肪性肝病（MASLD）进展 Pang, Zhongqiu; Zhang, Hui; Zheng, Shaoqin; More Hepatology. 82(3):702-721, September 2025. 17 Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles 血小板来源的线粒体通过细胞外囊泡调节非酒精性脂肪性肝炎的脂质代谢 Liao, Tsai-Ling; Chen, Der-Yuan; Hsieh, Shie-Liang; More Hepatology. 82(3):722-738, September 2025. Viral Hepatitis（病毒性肝炎） 18 Enhancing HBV-specific T cell responses through a combination of epigenetic modulation and immune checkpoint inhibition 通过表观遗传调控和免疫检查点抑制的联合增强HBV特异性T细胞反应 Urbanek-Quaing, Melanie; Chou, Yin-Han; Gupta, Manoj Kumar; More Hepatology. 82(3):739-754, September 2025. Reviews（综述） 19 Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis 重新评估传统凝血试验作为肝硬化再平衡凝血时代围手术期出血预测指标的价值 Tripodi, Armando; Primignani, Massimo; D’Ambrosio, Roberta; More Hepatology. 82(3):755-765, September 2025. 20 Defining an approach for therapeutic strategies in metabolic dysfunction–associated steatotic liver disease after liver transplantation 定义肝移植后代谢功能障碍相关脂肪性肝病的治疗策略方法 Siddiqui, Mohammad Shadab; Muthiah, Mark; Satapathy, Sanjaya K.; More Hepatology. 82(3):766-776, September 2025. 21 Adjuvant and neoadjuvant therapies for hepatocellular carcinoma 肝细胞癌的辅助治疗和新辅助治疗 Vogel, Arndt; Grant, Robert C.; Meyer, Tim; More Hepatology. 82(3):777-793, September 2025. Special Article（专题） 22 Value of HCC surveillance in a landscape of emerging surveillance options: Perspectives of a multi-stakeholder modified Delphi panel 新兴监测选择背景下肝细胞癌监测的价值：多利益相关者改良德尔菲小组的观点 Singal, Amit G.; Quirk, Lisa; Boike, Justin; More Hepatology. 82(3):794-809, September 2025. Practice Guidance（实践指南） 23 A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases 多学科方法诊断和管理威尔逊病：2022年美国肝病研究协会威尔逊病实践指南 Schilsky, Michael L.; Roberts, Eve A.; Bronstein, Jeff M.; More Hepatology. 82(3):E41-E90, September 2025. Correspondence（通信） 24 Letter to the Editor: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis? 致编辑的信：血浆FSTL-1水平能否作为晚期纤维化的可靠生物标志物？ Emanuele, Enzo; Minoretti, Piercarlo Hepatology. 82(3):E91, September 2025. 25 Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis? 回复：血浆FSTL-1水平能否作为晚期纤维化的可靠生物标志物？ Chi, Yongquan; Qi, Xiaolong; Rao, Jianhua Hepatology. 82(3):E92-E93, September 2025. 26 Letter to the Editor: Downstaging of hepatocellular carcinoma before liver transplantation—More details, more significance 致编辑的信：肝移植前肝细胞癌的降期治疗——更多细节，更多意义 Wang, Pusen; Zhong, Lin Hepatology. 82(3):E94-E95, September 2025. 27 Reply: Downstaging of hepatocellular carcinoma before liver transplantation—More details, more significance 回复：肝移植前肝细胞癌的降期治疗——更多细节，更多意义 Xu, Edison; Mehta, Neil Hepatology. 82(3):E96-E97, September 2025. 28 Letter to the Editor: Refining epigenetic insights in HBV-specific T-cell restoration 致编辑的信：完善HBV特异性T细胞恢复的表观遗传见解 Qiu, Yue Hepatology. 82(3):E98, September 2025. 29 Reply: Refining epigenetic insights in HBV-specific T-cell restoration 回复：完善HBV特异性T细胞恢复的表观遗传见解 Chou, Yin-Han; Cornberg, Markus Hepatology. 82(3):E99-E100, September 2025. 30 Letter to the Editor: Reflections on the predictors of long-term transplant-free survival after TIPS 致编辑的信：关于经颈静脉肝内门体分流术（TIPS）后长期无移植生存预测因素的思考 Qiu, Zhenkang; Yang, Guang; Gao, Fei Hepatology. 82(3):E101-E102, September 2025. 31 Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details 致编辑的信：经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂作为不可切除肝细胞癌转化治疗的生存获益需要更多细节 Wang, Dan; Yi, Shiming; Liu, Xia Hepatology. 82(3):E103-E104, September 2025. 32 Reply: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma needs more details 回复：经动脉化疗栓塞联合酪氨酸激酶抑制剂和免疫检查点抑制剂作为不可切除肝细胞癌转化治疗的生存获益需要更多细节 Yang, Da-Long; Li, Yi-Fan; Li, Yao-Jie; More Hepatology. 82(3):E105-E106, September 2025. 33 Letter to the Editor: TIPS for noncirrhotic adults with chronic mesenteric venous thrombosis and EHPVO refractory to standard-of-care therapy—How are they doing in 2025? 致编辑的信：非肝硬化成人慢性肠系膜静脉血栓形成和肝外门静脉阻塞（EHPVO）对标准治疗耐药的TIPS治疗——2025年情况如何？ Knight, Gabriel M.; Boike, Justin; Thornburg, Bartley; More Hepatology. 82(3):E107-E108, September 2025. 34 Letter to the Editor: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis 致编辑的信：糖尿病和非糖尿病患者经活检证实的代谢功能障碍相关脂肪变性的肝脏硬度进展比较 Zuo, Zhongbao; Yang, Chunli; Wang, Miaochan; More Hepatology. 82(3):E109-E110, September 2025. 35 Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis 回复：糖尿病和非糖尿病患者经活检证实的代谢功能障碍相关脂肪变性的肝脏硬度进展比较 Huang, Daniel Q.; Loomba, Rohit Hepatology. 82(3):E111-E112, September 2025. Erratum（勘误） 36 Erratum: HAF prevents hepatocyte apoptosis and progression to MASH and HCC through transcriptional regulation of the NF-κB pathway 勘误：HAF通过NF-κB通路的转录调控防止肝细胞凋亡和进展为代谢相关脂肪性肝炎（MASH）和肝细胞癌 Acuña-Pilarte, Karen; Reichert, Ethan C.; Green, Yangsook Song; More Hepatology. 82(3):E113, September 2025. Retraction（撤稿） 37 Retraction: Blocking H1/H2 histamine receptors inhibits damage/fibrosis in Mdr2−/− mice and human cholangiocarcinoma tumorigenesis 撤稿：阻断H1/H2组胺受体可抑制Mdr2−/−小鼠的损伤/纤维化和人胆管癌肿瘤发生 Kennedy, Lindsey; Hargrove, Laura; Demieville, Jennifer; More Hepatology. 82(3):E114, September 2025. Hepatology[Jour] AND 82[volume] AND 4[issue] 肝脏病学 82卷4期 https://journals-lww-com.libproxy1.nus.edu.sg/hep/pages/currenttoc.aspx Editorial（社论） 1 The dynamic landscape of cholestatic liver disease 胆汁淤积性肝病的动态变化特征 Gores, Gregory J.; Malhi, Harmeet Hepatology. 82(4):811-812, October 2025. Reviews（综述） 2 Epidemiological and economical burden of cholestatic liver disease 胆汁淤积性肝病的流行病学及经济负担 Mol, Bregje; Werner, Ellen; Culver, Emma L.; More Hepatology. 82(4):813-833, October 2025. 3 Central role for cholangiocyte pathobiology in cholestatic liver diseases 胆管细胞病理生物学在胆汁淤积性肝病中的核心作用 Jalan-Sakrikar, Nidhi; Guicciardi, Maria Eugenia; O’Hara, Steven P.; More Hepatology. 82(4):834-854, October 2025. 4 Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease 胆汁淤积性肝病中胆汁酸循环治疗靶点的益处与挑战 Trauner, Michael; Karpen, Saul J.; Dawson, Paul A. Hepatology. 82(4):855-876, October 2025. 5 The immunological landscape of primary biliary cholangitis: Mechanisms and therapeutic prospects 原发性胆汁性胆管炎的免疫学特征：机制与治疗前景 Ronca, Vincenzo; Davies, Scott P.; Oo, Ye Htun; More Hepatology. 82(4):877-894, October 2025. 6 Primary biliary cholangitis: Personalizing second-line therapies 原发性胆汁性胆管炎：二线治疗的个体化选择 Levy, Cynthia; Bowlus, Christopher L. Hepatology. 82(4):895-910, October 2025. 7 Immunobiology of primary sclerosing cholangitis 原发性硬化性胆管炎的免疫生物学 Cornillet, Martin; Geanon, Daniel; Bergquist, Annika; More Hepatology. 82(4):911-926, October 2025. 8 Medical treatment of primary sclerosing cholangitis: What have we learned and where are we going? 原发性硬化性胆管炎的药物治疗：我们学到了什么以及未来方向何在？ Karlsen, Tom H.; Kaasen Jørgensen, Kristin; Bergquist, Annika Hepatology. 82(4):927-948, October 2025. 9 Identifying a therapeutic window of opportunity for people living with primary sclerosing cholangitis: Embryology and the overlap of inflammatory bowel disease with immune-mediated liver injury 为原发性硬化性胆管炎患者确定治疗时机窗口：胚胎学与炎症性肠病和免疫介导的肝损伤重叠 Kellermayer, Richard; Carbone, Marco; Horvath, Thomas D.; More Hepatology. 82(4):949-959, October 2025. 10 PSC and colitis: A complex relationship 原发性硬化性胆管炎与结肠炎：复杂的关系 Horst, Ludwig J.; Kempski, Jan; Walmsley, Martine; More Hepatology. 82(4):960-984, October 2025. 11 IBAT inhibitors in pediatric cholestatic liver diseases: Transformation on the horizon? 回肠胆汁酸转运蛋白（IBAT）抑制剂在儿童胆汁淤积性肝病中的应用：变革即将来临？ Sutton, Harry; Sokol, Ronald J.; Kamath, Binita M. Hepatology. 82(4):985-995, October 2025. 12 Drug-induced cholestatic liver diseases 药物性胆汁淤积性肝病 Bjornsson, Einar S.; Devarbhavi, Harshad C. Hepatology. 82(4):996-1015, October 2025. 13 Liver transplantation for cholestatic liver diseases: Timing and disease recurrence 胆汁淤积性肝病的肝移植：时机与疾病复发 Cançado, Guilherme Grossi Lopes; Deeb, Maya; Gulamhusein, Aliya F. Hepatology. 82(4):1016-1035, October 2025. Hepatology[Jour] AND 82[volume] AND 5[issue] 肝脏病学 82卷5期 https://journals-lww-com.libproxy1.nus.edu.sg/hep/pages/currenttoc.aspx Hepatology Highlights（肝病学亮点） 1 When “remission” isn’t enough: The unseen burden of autoimmune hepatitis 当“缓解”尚不足够：自身免疫性肝炎未被察觉的负担 Sidhu, Guneet Hepatology. 82(5):1037-1038, November 2025. 2 Surgical resection for hepatocellular carcinoma: Leave no TACE? 肝细胞癌的手术切除：是否不再需要经导管动脉化疗栓塞术（TACE）？ Khalid, Mian B.; Ilyas, Sumera I. Hepatology. 82(5):1039-1040, November 2025. 3 Bundle it up—Care bundles for spontaneous bacterial peritonitis 打包处理——自发性细菌性腹膜炎的护理方案组合 Kanagalingam, Gowthami; Arab, Juan Pablo Hepatology. 82(5):1041-1042, November 2025. 4 Who improves, who doesn’t and why? Defining improvement and drivers of outcomes in pediatric MASLD 哪些患者病情会改善，哪些不会，原因何在？儿童代谢相关脂肪性肝病（MASLD）中病情改善的定义及预后驱动因素 Harris, Kevin B.; Ilyas, Sumera I. Hepatology. 82(5):1043-1044, November 2025. Commentary（述评） 5 Building hepatitis B virus gene transcription from the bottom up 自下而上构建乙型肝炎病毒基因转录 Gómez-Moreno, Andoni; Bradley, Daniel; Ploss, Alexander Hepatology. 82(5):1045-1047, November 2025. Editorials（社论） 6 The impact of LRP4 mutations on HCC recurrence and immunotherapy response LRP4突变对肝细胞癌复发和免疫治疗反应的影响 Lu, Zhen; Wong, Chun-Ming Hepatology. 82(5):1048-1050, November 2025. 7 Check(point)s and balances: ‘Know thy enemy’ （免疫）检查点与平衡：“知己知彼” Watt, Kymberly D. Hepatology. 82(5):1051-1052, November 2025. 8 Identifying the sweet spot in portal pressure reduction with TIPS 利用经颈静脉肝内门体分流术（TIPS）降低门静脉压力的“最佳点”识别 China, Louise; Patch, David Hepatology. 82(5):1053-1055, November 2025. 9 Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination 肝硬化和肝癌的分化趋势凸显了消除肝炎所需的持续努力 Wong, Grace Lai-Hung; Chan, Henry Lik-Yuen Hepatology. 82(5):1056-1057, November 2025. Original Articles（论著） Immune-Mediated Diseases, DILI, and Biliary Tract Disease（免疫介导性疾病、药物性肝损伤和胆道疾病） 10 Health-related quality of life is impaired in people with autoimmune hepatitis: Results of a multicentre cross-sectional study within the European Reference Network 自身免疫性肝炎患者健康相关生活质量受损：欧洲参考网络内一项多中心横断面研究的结果 Snijders, Romée J.A.L.M.; Janik, Maciej K.; Mund, Meike; More Hepatology. 82(5):1058-1072, November 2025. Liver Cancer（肝癌） 11 LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma LRP4突变促进复发性肝细胞癌的肿瘤进展及抗PD-1治疗耐药性 Sun, Rongqi; Liu, Kaixuan; Pan, Siyuan; More Hepatology. 82(5):1073-1089, November 2025. 12 Aptamer-directed, nanovesicle-mediated targeting of undruggable molecules in preclinical cholangiocarcinoma models 在临床前胆管癌模型中，利用适配体引导纳米囊泡靶向不可成药分子 Yu, Mincheng; Sample, Jack W.; Yan, Irene K.; More Hepatology. 82(5):1090-1111, November 2025. 13 Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial 肝细胞癌根治性切除术后辅助经导管动脉化疗栓塞术：一项随机、开放标签、3期试验 Ma, Tao; Bai, Xueli; Zhang, Qi; More Hepatology. 82(5):1112-1121, November 2025. 14 Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study 肝移植前免疫检查点抑制剂的安全停药期确定：一项国际回顾性队列研究 Moeckli, Beat; Wassmer, Charles-Henri; El Hajji, Sofia; More Hepatology. 82(5):1122-1137, November 2025. Liver Pathobiology（肝脏病理生物学） 15 Repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury 成纤维细胞生长因子4（FGF4）抑制ERRγ-CYP2E1通路可减轻酒精相关性肝损伤 Wang, Luyao; Dong, Wenliya; Fan, Lei; More Hepatology. 82(5):1138-1154, November 2025. Liver Failure/Cirrhosis/Portal Hypertension（肝衰竭/肝硬化/门静脉高压） 16 End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective TIPS in patients with cirrhosis 肝硬化患者选择性经颈静脉肝内门体分流术（TIPS）中，手术结束时遵循推荐血流动力学目标并未改善预后 Roccarina, Davide; Saltini, Dario; Adotti, Valentina; More Hepatology. 82(5):1155-1171, November 2025. 17 Identification of optimal portal pressure decrease to control ascites while minimizing HE after TIPS: A multicenter study 确定TIPS术后控制腹水同时使肝性脑病（HE）最小化的最佳门静脉压力下降值：一项多中心研究 Kabelitz, Martin A.; Hartl, Lukas; Schaub, Golda; More Hepatology. 82(5):1172-1186, November 2025. 18 Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study 自发性细菌性腹膜炎的临床预后和护理：一项全国队列研究 Serper, Marina; Tang, Helen; Zhang, Siqi; More Hepatology. 82(5):1187-1197, November 2025. Pediatrics（儿科） 19 Longitudinal response to standard of care in pediatric metabolic dysfunction–associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes 儿童代谢相关脂肪性肝病对标准治疗的纵向反应：改善和恶化的比率以及与预后相关的因素 Newton, Kimberly P.; Jayasekera, Dulshan; Blackford, Amanda L.; More Hepatology. 82(5):1198-1210, November 2025. Steatohepatitis（脂肪性肝炎） 20 CD44 in myeloid cells is a major driver of liver inflammation and injury in alcohol-associated liver disease 髓系细胞中的CD44是酒精相关性肝病中肝脏炎症和损伤的主要驱动因素 Rousseau, Déborah; Bonnafous, Stéphanie; Soysouvanh, Frédéric; More Hepatology. 82(5):1211-1228, November 2025. 21 Prevalence and predictors of cirrhosis and portal hypertension in the United States 美国肝硬化和门静脉高压的患病率及预测因素 Younossi, Zobair M.; de Avila, Leyla; Racila, Andrei; More Hepatology. 82(5):1229-1240, November 2025. 22 Corticosteroids in severe alcohol-associated hepatitis. Not so fast: A systematic review of randomized controlled trials 糖皮质激素治疗重症酒精相关性肝炎：且慢！一项随机对照试验的系统综述 Shi, Michael A.; Pungwe, Prisca; Comer, Lauren L.M.; More Hepatology. 82(5):1241-1255, November 2025. 23 Prevalence of metabolic dysfunction–associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data 利用2017年-2020年3月及2021年8月-2023年8月美国国家健康与营养检查调查数据，分析美国代谢相关脂肪性肝病和肝纤维化的患病率 Unalp-Arida, Aynur; Ruhl, Constance E. Hepatology. 82(5):1256-1273, November 2025. Viral Hepatitis（病毒性肝炎） 24 Global burden of HBV-related liver disease: Primary liver cancer due to chronic HBV infection increased in over one-third of countries globally from 2000 to 2021 全球乙型肝炎病毒（HBV）相关肝病的负担：2000年至2021年，全球超过三分之一的国家因慢性HBV感染导致的原发性肝癌病例增加 Danpanichkul, Pojsakorn; Duangsonk, Kwanjit; Chen, Vincent L.; More Hepatology. 82(5):1274-1286, November 2025. Reviews（综述） 25 Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations 胆道癌的新辅助治疗和辅助治疗：进展与局限 Wilbur, H. Catherine; Soares, Heloisa P.; Azad, Nilofer S. Hepatology. 82(5):1287-1302, November 2025. 26 Molecular mechanisms in MASLD/MASH-related HCC 代谢相关脂肪性肝病/代谢相关脂肪性肝炎相关肝细胞癌的分子机制 Wang, Xiaobo; Zhang, Liang; Dong, Bingning Hepatology. 82(5):1303-1324, November 2025. 27 MASH clinical trials and drugs pipeline: An impending tsunami MASH临床试验及药物研发管线：一场即将到来的海啸 Noureddin, Mazen Hepatology. 82(5):1325-1340, November 2025. Special Articles（专题论著） 28 Call to action—Pediatric MASLD requires immediate attention to curb health crisis 行动呼吁——儿童代谢相关脂肪性肝病需立即关注以遏制健康危机 Hartmann, Phillipp; Mouzaki, Marialena; Hassan, Sara; More Hepatology. 82(5):1341-1351, November 2025. 29 AASLD Practice Statement on the evaluation and management of metabolic dysfunction–associated steatotic liver disease in children 美国肝病研究协会（AASLD）关于儿童代谢相关脂肪性肝病评估和管理的实践声明 Xanthakos, Stavra A.; Ibrahim, Samar H.; Adams, Kathryn; More Hepatology. 82(5):1352-1394, November 2025. Fellows' Corner（研究员园地） 30 Fellows’ Corner 研究员园地 Deeb, Maya Hepatology. 82(5):E115-E116, November 2025. Visual Brief（速览） 31 Diagnosis and Management of Hepatocellular Carcinoma 肝细胞癌的诊断与治疗 Hepatology. 82(5):E117-E120, November 2025. Correspondence（读者来信） 32 Letter to the Editor: The divergences in the efficacy of adjuvant transarterial chemoembolization for HCC—In-depth analysis and enlightenments 致编辑的信：肝细胞癌辅助经导管动脉化疗栓塞术疗效的差异——深入分析与启示 Chen, Shuanggang; Shen, Lujun; Fan, Weijun Hepatology. 82(5):E121-E122, November 2025. 33 Letter to the Editor: Redefining post-resection care: Critical analysis of adjuvant TACE in curative HCC management 致编辑的信：重新定义术后护理：对根治性肝细胞癌治疗中辅助经导管动脉化疗栓塞术的批判性分析 Zhang, Qianqian; Song, Quanmao; Liu, Yanna; More Hepatology. 82(5):E123, November 2025. 34 Letter to the Editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients 致编辑的信：肝硬化患者术后经颈静脉肝内门体分流术（TIPS）血流动力学目标达标未能改善预后 Tantai, Xinxing; Li, Lu; Dai, Shejiao Hepatology. 82(5):E124-E125, November 2025. 35 Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients 回复：肝硬化患者术后经颈静脉肝内门体分流术（TIPS）血流动力学目标达标未能改善预后 Roccarina, Davide; Saltini, Dario; Senzolo, Marco; More Hepatology. 82(5):E126-E127, November 2025. 36 Letter to the Editor: Antibody-mediated rejection in liver transplantation following immune checkpoint inhibitors treatment 致编辑的信：免疫检查点抑制剂治疗后肝移植中的抗体介导的排斥反应 Wang, Pusen; Zhong, Lin Hepatology. 82(5):E128-E129, November 2025. 37 Reply: Antibody-mediated rejection in liver transplantation following immune checkpoint inhibitors treatment 回复：免疫检查点抑制剂治疗后肝移植中的抗体介导的排斥反应 Moeckli, Beat; Lanz, Loyse; Rodríguez-Perálvarez, Manuel; More Hepatology. 82(5):E130-E131, November 2025. 38 Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function 致编辑的信：关于肝星状细胞调节肝细胞功能过程中LHX2特定作用的思考 Ni, Jiaping; Zhai, Dongqing; Li, Jintong; More Hepatology. 82(5):E132-E133, November 2025. 39 Reply: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function 回复：关于肝星状细胞调节肝细胞功能过程中LHX2特定作用的思考 Tao, Jiawang; Wang, Jie Hepatology. 82(5):E134-E135, November 2025. 40 Letter to the Editor: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy 致编辑的信：澄清免疫治疗后肝细胞癌患者中疗效标准及局部区域治疗对完全缓解预后的影响 Liu, Tsung-Hao; Yang, Hung-Chih Hepatology. 82(5):E136-E137, November 2025. 41 Reply: Clarifying the impact of response criteria and locoregional therapy on complete response outcomes in patients with hepatocellular carcinoma following immunotherapy 回复：澄清免疫治疗后肝细胞癌患者中疗效标准及局部区域治疗对完全缓解预后的影响 Scheiner, Bernhard; Pinter, Matthias Hepatology. 82(5):E138-E139, November 2025.